Clear Catheter nabs $4M in first round of financing; Uptake raises $35M to develop emphysema tech;

> Clear Catheter Systems has closed its first institutional round of financing. The $4 million round was co-led by Aphelion Capital and California Technology Ventures with Research Corporation Technologies joining in. The company will use the capital to respond to increasing demand for its lead product--the PleuraFlow active tube clearance system--and to drive commercialization efforts in the U.S. and abroad. Clear Catheter release

> Uptake Medical has raised $35 million of a $41 million venture capital round, according to an SEC filing. The company is developing new medical device technologies to treat emphysema. Report

> iCAD ($ICAD), which provides advanced image analysis, work flow solutions and radiation therapy for the early identification and treatment of cancer, has entered into a 5-year, $15 million debt facility agreement with Deerfield Management Company. iCAD release

> The Centers for Medicare and Medicaid Services has acknowledged substantial clinical improvement associated with the use of Boston Scientific's ($BSX) Alair bronchial thermoplasty system for the management of severe asthma. Boston Scientific release

> Given Imaging ($GIVN) says roughly 700 patients have been enrolled in the PillCam COLON 2 pivotal trial, and more than 500 patients have ingested PillCam COLON 2 in the trial. Given Imaging release

> The EndoBarrier gastrointestinal liner, which is used to treat Type 2 diabetes and obesity, has been transitioned to commercial use in the Netherlands, according to GI Dynamics ($GID). GI Dynamics release

> Novadaq Technologies has signed an agreement naming MAQUET Cardiovascular as the exclusive distributor of Novadaq's CO2 heart laser systems and procedure kits in the U.S. Novadaq/MAQUET release

And Finally... A Synthes ($SYST) unit is accusing rival Stryker ($SYK) of raiding its San Francisco-based sales force and using confidential information from those ex-employees to its advantage. Report

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.